126 related articles for article (PubMed ID: 34058670)
1. "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
Walker S; Wallace J; Latham N; Saich F; Pedrana A; Hellard M; Treloar C; Marukutira T; Higgs P; Doyle J; Stoové M
Int J Drug Policy; 2021 Nov; 97():103280. PubMed ID: 34058670
[TBL] [Abstract][Full Text] [Related]
2. Connecting patients notified with hepatitis C to treatment (CONNECT Study): A randomized controlled trial of active case management by a health department to support primary care practitioners.
Marukutira T; Barter R; Moore KP; Hellard ME; Richmond J; Turner K; Pedrana AE; Melody S; Johnston FH; Owen L; Boom WVD; Scott N; Thompson A; Iser DM; Spelman T; Veitch M; Stoové M; Doyle JS
Int J Drug Policy; 2023 Nov; 121():104184. PubMed ID: 37714008
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol.
Marukutira T; Moore KP; Hellard M; Richmond J; Turner K; Pedrana AE; Melody S; Johnston FH; Owen L; Van Den Boom W; Scott N; Thompson A; Iser D; Spelman T; Veitch M; Stoové MA; Doyle J
BMJ Open; 2022 Mar; 12(3):e056120. PubMed ID: 35338062
[TBL] [Abstract][Full Text] [Related]
4. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
5. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
6. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
7. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
8. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.
Gidding HF; Topp L; Middleton M; Robinson K; Hellard M; McCaughan G; Maher L; Kaldor JM; Dore GJ; Law MG
J Gastroenterol Hepatol; 2009 Oct; 24(10):1648-54. PubMed ID: 19798783
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
[TBL] [Abstract][Full Text] [Related]
11. The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016.
Edmunds BL; Miller ER; Tsourtos G
BMC Public Health; 2019 May; 19(1):527. PubMed ID: 31068170
[TBL] [Abstract][Full Text] [Related]
12. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV
Clin Infect Dis; 2020 Sep; 71(6):1502-1510. PubMed ID: 31585005
[TBL] [Abstract][Full Text] [Related]
13. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
14. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
[TBL] [Abstract][Full Text] [Related]
15. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
16. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
17. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'?
Heard E; Massi L; Smirnov A; Selvey LA
Intern Med J; 2020 Sep; 50(9):1053-1058. PubMed ID: 31589351
[TBL] [Abstract][Full Text] [Related]
18. Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders.
Chan HK; Hassali MA; Mohammed NS; Azlan A; Hassan MRA
BMC Public Health; 2022 Feb; 22(1):371. PubMed ID: 35189876
[TBL] [Abstract][Full Text] [Related]
19. Using notifications data to increase hepatitis C testing and treatment rates in Queensland.
Carpenter M; Selvey LA; Lambert SB; Kemp R
Commun Dis Intell (2018); 2023 Oct; 47():. PubMed ID: 37857557
[TBL] [Abstract][Full Text] [Related]
20. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
Dore GJ; Hajarizadeh B
Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
